Vanda Pharmaceuticals | VNDA - Cash And Equivalent


Vanda Pharmaceuticals reported $84.85M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 1.91B 687M Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Veracyte USD 263.14M 99.44M Mar/2026